Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé.
Pautier P, Genestie C, Gladieff L, Kurtz JE, Lortholary A, de La Motte Rouge T, Gaillard AL, Ducassou A, Dubot C, Rouleau E, Narducci F, Demontoy S, Hennequin C. Pautier P, et al. Among authors: de la motte rouge t. Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8. Bull Cancer. 2023. PMID: 37573038 French.
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours.
Hollande C, Colin P, de La Motte Rouge T, Audenet F, Yates DR, Phé V, Ouzzane A, Droupy S, Ruffion A, de La Taille A, Guy L, Cussenot O, Rozet F, Xylinas E, Zerbib M, Spano JP, Khayat D, Bitker MO, Rouprêt M; French Collaborative National Working-Group on UTUC. Hollande C, et al. Among authors: de la taille a, de la motte rouge t. BJU Int. 2014 Apr;113(4):574-80. doi: 10.1111/bju.12308. Epub 2013 Aug 13. BJU Int. 2014. PMID: 23937547
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
Rini BI, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Grünwald V, Ingrosso A, Tortorici MA, Bycott P, Kim S, Bloom J, Motzer RJ. Rini BI, et al. Among authors: de la motte rouge t. Clin Genitourin Cancer. 2013 Jun;11(2):107-14. doi: 10.1016/j.clgc.2012.12.004. Epub 2013 Feb 4. Clin Genitourin Cancer. 2013. PMID: 23391371 Clinical Trial.
Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.
Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ. Brown J, et al. Among authors: de la motte rouge t. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Int J Gynecol Cancer. 2014. PMID: 25341580 Review.
[Medical treatment of metastatic or recurrent cancer of the cervix].
de la Motte Rouge T, Pautier P, Hamy AS, Duvillard P, Bruna A, Castaigne D, Morice P, Haie-Meder C, Lhommé C. de la Motte Rouge T, et al. Bull Cancer. 2006 Mar 1;93(3):263-70. Bull Cancer. 2006. PMID: 16567313 Free article. Review. French.
[Ovarian yolk sac tumour: general review].
Even C, Lhommé C, Duvillard P, Morice P, Balleyguier C, Pautier P, Troalen F, de La Motte Rouge T. Even C, et al. Among authors: de la motte rouge t. Bull Cancer. 2011 Aug;98(8):963-75. doi: 10.1684/bdc.2011.1387. Bull Cancer. 2011. PMID: 21708513 Free article. Review. French.
[Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R, De La Motte Rouge T, Dubot C, Leary A, Lhommé C, Pautier P, Scholl S, Rodrigues MJ. Geiss R, et al. Among authors: de la motte rouge t. Bull Cancer. 2014 Jul-Aug;101(7-8):748-55. doi: 10.1684/bdc.2014.1949. Bull Cancer. 2014. PMID: 25091657 Review. French.
111 results